Dyslipidemia Epidemiology Forecasts

DelveInsight’s ‘Dyslipidemia – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.

Geographies Covered

  • Portugal 
  • Switzerland 
  • Greece
  • Turkey
  • Poland
  • Netherlands
  • Belgium
  • Austria

Study Period: 2019–2032

Dyslipidemia: Disease Understanding

Dyslipidemia Overview

Dyslipidemias (defined as raised plasma concentrations of total cholesterol, LDL cholesterol or triglycerides, or a low plasma concentration of HDL cholesterol or a combination of these features) are major risk factors for ischemic heart disease (IHD).

 

This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications. These lipids are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of these factors, either from organic or nonorganic causes, can lead to dyslipidemia.

 

It is divided into two types, primary and secondary. Primary dyslipidemia comes through genes, and secondary dyslipidemia is acquired, which is developed from other issues like obesity or diabetes. Hyperlipidemia is often confused with dyslipidemia. Hyperlipidemia is caused when LDL levels are high, but dyslipidemia is caused by blood fats being either low or high. Hyperlipidemia is a major cause of atherosclerosis, and it includes conditions like ischemic cardiovascular issues, coronary heart disease, and peripheral vascular disease.

 

High cholesterol has no symptoms, and a blood test is the only way to detect it. History is essential in identifying high-risk individuals. Most importantly, social history would include tobacco use or specific details about diet. Past medical history is vital in identifying patients who need primary prevention versus secondary prevention if statin therapy requires initiation. Lastly, family history is vital to identify.

Dyslipidemia: Epidemiology

The dyslipidemia epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and trends, along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted dyslipidemia epidemiology segmented as the prevalent cases of dyslipidemia, diagnosed cases of dyslipidemia, gender-specific diagnosed cases of dyslipidemia, prevalence of genetic dyslipidemia by types and lipid-specific diagnosed cases. The report includes the prevalent scenario of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria from 2019 to 2032.

Country-wise Dyslipidemia Epidemiology

The epidemiology segment also provides the dyslipidemia epidemiology data and findings across Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.

  • Total prevalent cases of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) was approximately 83 million cases in 2021.
  • According to the estimates, Turkey had the most prevalent dyslipidemia in 2021. On the other hand, Portugal had the lowest prevalent population with approximately 3.4 million cases in 2021.

Scope of the Report

  • Dyslipidemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • Dyslipidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria).
  • The report provides insight into the historical and forecasted patient pool of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
  • The report helps recognize the growth opportunities in the emerging markets concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of dyslipidemia.
  • The report provides the segmentation of the dyslipidemia epidemiology by prevalent cases of dyslipidemia in the emerging markets.
  • The report provides the segmentation of the dyslipidemia epidemiology by diagnosed prevalent cases of dyslipidemia in the emerging markets.
  • The report provides the segmentation of the dyslipidemia epidemiology by Gender-specific cases of dyslipidemia in emerging markets.
  • The report provides the segmentation of the dyslipidemia epidemiology by Prevalence of genetic dyslipidemia by types in emerging markets.
  • The report provides the segmentation of the dyslipidemia epidemiology by Lipid-specific cases of dyslipidemia in emerging markets.

Report Highlights

  • 11-year Forecast of Dyslipidemia epidemiology
  • Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria Coverage
  • Prevalent cases of dyslipidemia
  • Diagnosed cases of dyslipidemia
  • Gender-specific diagnosed cases of dyslipidemia
  • Prevalence of genetic dyslipidemia by types
  • Lipid-specific diagnosed cases of dyslipidemia

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in patient population with dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) during the forecast period (2019–2032)?
  • What are the key findings pertaining to dyslipidemia epidemiology across emerging markets, and which country will have the highest number of patients during the forecast period (2019–2032)?
  • What would be the total number of patients with dyslipidemia across the emerging markets during the forecast period (2019–2032)?
  • At what CAGR is the patient population expected to grow in the emerging markets forecast period (2019–2032)?
  • What are the disease risk, burdens, and unmet needs of dyslipidemia?
  • What are the currently available treatments for dyslipidemia?

Reasons to buy

Dyslipidemia Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market
  • Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans
  • Understand the magnitude of the dyslipidemia population by its prevalent cases.
  • Understand the magnitude of the dyslipidemia population by its gender-specific cases.
  • Understand the magnitude of the dyslipidemia population by its prevalence of genetic dyslipidemia by types.
  • Understand the magnitude of the dyslipidemia population by its lipid-specific diagnosed cases of dyslipidemia.
  • The dyslipidemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The dyslipidemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Dyslipidemia Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Dyslipidemia in 2019

3.2. Patient Share (%) Distribution of Dyslipidemia in 2032

4. Executive Summary of Dyslipidemia

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Etiology

5.5. Pathogenesis

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Prevalent Cases of Dyslipidemia in the Emerging Markets

6.3. Assumptions and Rationale

6.4. Portugal

6.4.1. Prevalent Cases of Dyslipidemia in Portugal

6.4.2. Diagnosed Cases of Dyslipidemia in Portugal

6.4.3. Gender-specific Diagnosed Cases of Dyslipidemia in Portugal

6.4.4. Prevalence of Genetic Dyslipidemia by Types in Portugal

6.4.5. Lipid-specific Diagnosed Cases in Portugal

6.5. Switzerland

6.5.1. Prevalent Cases of Dyslipidemia in Switzerland

6.5.2. Diagnosed Cases of Dyslipidemia in Switzerland

6.5.3. Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland

6.5.4. Prevalence of Genetic Dyslipidemia by Types in Switzerland

6.5.5. Lipid-specific Diagnosed Cases in Switzerland

6.6. Greece

6.6.1. Prevalent Cases of Dyslipidemia in Greece

6.6.2. Diagnosed Cases of Dyslipidemia in Greece

6.6.3. Gender-specific Diagnosed Cases of Dyslipidemia in Greece

6.6.4. Prevalence of Genetic Dyslipidemia by Types in Greece

6.6.5. Lipid-specific Diagnosed Cases in Greece

6.7. Turkey

6.7.1. Prevalent Cases of Dyslipidemia in Turkey

6.7.2. Diagnosed Cases of Dyslipidemia in Turkey

6.7.3. Gender-specific Diagnosed Cases of Dyslipidemia in Turkey

6.7.4. Prevalence of Genetic Dyslipidemia by Types in Turkey

6.7.5. Lipid-specific Diagnosed Cases in Turkey

6.8. Poland

6.8.1. Prevalent Cases of Dyslipidemia in Poland

6.8.2. Diagnosed Cases of Dyslipidemia in Poland

6.8.3. Gender-specific Diagnosed Cases of Dyslipidemia in Poland

6.8.4. Prevalence of Genetic Dyslipidemia by Types in Poland

6.8.5. Lipid-specific Diagnosed Cases in Poland

6.9. Netherlands

6.9.1. Prevalent Cases of Dyslipidemia in the Netherlands

6.9.2. Diagnosed Cases of Dyslipidemia in the Netherlands

6.9.3. Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands

6.9.4. Prevalence of Genetic Dyslipidemia by Types in the Netherlands

6.9.5. Lipid-specific Diagnosed Cases in the Netherlands

6.10. Belgium

6.10.1. Prevalent Cases of Dyslipidemia in Belgium

6.10.2. Diagnosed Cases of Dyslipidemia in Belgium

6.10.3. Gender-specific Diagnosed Cases of Dyslipidemia in Belgium

6.10.4. Prevalence of Genetic Dyslipidemia by Types in Belgium

6.10.5. Lipid-specific Diagnosed Cases in Belgium

6.11. Austria

6.11.1. Prevalent Cases of Dyslipidemia in Austria

6.11.2. Diagnosed Cases of Dyslipidemia in Austria

6.11.3. Gender-specific Diagnosed Cases of Dyslipidemia in Austria

6.11.4. Prevalence of Genetic Dyslipidemia by Types in Austria

6.11.5. Lipid-specific Diagnosed Cases in Austria

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Dyslipidemia: Epidemiology (2019–2032)

Table 2: Genetic classification of Dyslipidemia

Table 3: The Criteria for Diagnosis of Dyslipidemia

Table 4: Total Diagnosed Prevalent Population of Dyslipidemia (2019–2032)

Table 5: Prevalent Cases of Dyslipidemia in Portugal (2019–2032)

Table 6: Diagnosed Cases of Dyslipidemia in Portugal (2019–2032)

Table 7: Gender-specificspecific Diagnosed Cases of Dyslipidemia in Portugal (2019–2032)

Table 8: Prevalence of Genetic Dyslipidemia by Types in Portugal (2019–2032)

Table 9: Lipid-specific Diagnosed Cases in Portugal (2019–2032)

Table 10: Prevalent Cases of Dyslipidemia in Switzerland (2019–2032)

Table 11: Diagnosed Cases of Dyslipidemia in Switzerland (2019–2032)

Table 12: Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland (2019–2032)

Table 13: Prevalence of Genetic Dyslipidemia by Types in Switzerland (2019–2032)

Table 14: Lipid-specific Diagnosed Cases in Switzerland (2019–2032)

Table 15: Prevalent Cases of Dyslipidemia in Greece (2019–2032)

Table 16: Diagnosed Cases of Dyslipidemia in Greece (2019–2032)

Table 17: Gender-specific Diagnosed Cases of Dyslipidemia in Greece (2019–2032)

Table 18: Prevalence of Genetic Dyslipidemia by Types in Greece (2019–2032)

Table 19: Lipid-specific Diagnosed Cases in Greece (2019–2032)

Table 20: Prevalent Cases of Dyslipidemia Turkey (2019–2032)

Table 21: Diagnosed Cases of Dyslipidemia in Turkey (2019–2032)

Table 22: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey (2019–2032)

Table 23: Prevalence of Genetic Dyslipidemia by Types in Turkey (2019–2032)

Table 24: Lipid-specific Diagnosed Cases in Turkey (2019–2032)

Table 25: Prevalent Cases of Dyslipidemia Poland (2019–2032)

Table 26: Diagnosed Cases of Dyslipidemia in Poland (2019–2032)

Table 27: Gender-specific Diagnosed Cases of Dyslipidemia Poland (2019–2032)

Table 28: Prevalence of Genetic Dyslipidemia by Types in Poland (2019–2032)

Table 29: Lipid-specific Diagnosed Cases Poland (2019–2032)

Table 30: Prevalent Cases of Dyslipidemia in the Netherlands (2019–2032)

Table 31: Diagnosed Cases of Dyslipidemia in the Netherlands (2019–2032)

Table 32: Gender-specific Diagnosed Cases of Dyslipidemia in Netherlands 000’s (2019–2032)

Table 33: Prevalence of Genetic Dyslipidemia by Types in Netherlands 000’s (2019–2032)

Table 34: Lipid-specific Diagnosed Cases in the Netherlands (2019–2032)

Table 35: Prevalent Cases of Dyslipidemia in Belgium (2019–2032)

Table 36: Diagnosed Cases of Dyslipidemia in Belgium 000’s (2019–2032)

Table 37: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium (2019–2032)

Table 38: Prevalence of Genetic Dyslipidemia by Types in Belgium (2019–2032)

Table 39: Lipid-specific Diagnosed Cases in Belgium (2019–2032)

Table 40: Prevalent Cases of Dyslipidemia in Austria (2019–2032)

Table 41: Diagnosed Cases of Dyslipidemia in Austria (2019–2032)

Table 42: Gender-specific Diagnosed Cases of Dyslipidemia in Austria (2019–2032)

Table 43: Prevalence of Genetic Dyslipidemia by Types in Austria (2019–2032)

Table 44: Lipid-specific Diagnosed Cases in Austria (2019–2032)

List of Figures

Figure 1: Dyslipidemic states

Figure 2: Classification of Dyslipidemia

Figure 3: Eyelid Xanthelasmas

Figure 4: Tendinous xanthomas at the Achilles

Figure 5: Xanthomas over back

Figure 6: Causes of Dyslipidemia

Figure 7: Total Prevalent Cases of Dyslipidemia in the Emerging Markets (2019–2032)

Figure 8: Prevalent Cases of Dyslipidemia in Portugal (2019–2032)

Figure 9: Diagnosed Cases of Dyslipidemia in Portugal (2019–2032)

Figure 10: Gender-specific Diagnosed Cases of Dyslipidemia in Portugal (2019–2032)

Figure 11: Prevalence of Genetic Dyslipidemia by Types in Portugal (2019–2032)

Figure 12: Lipid-specific Diagnosed Cases in Portugal (2019–2032)

Figure 13: Prevalent Cases of Dyslipidemia in Switzerland (2019–2032)

Figure 14: Diagnosed Cases of Dyslipidemia in Switzerland (2019–2032)

Figure 15: Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland (2019–2032)

Figure 16: Prevalence of Genetic Dyslipidemia by Types in Switzerland (2019–2032)

Figure 17: Lipid-specific Diagnosed Cases in Switzerland (2019–2032)

Figure 18: Prevalent Cases of Dyslipidemia in Greece (2019–2032)

Figure 19: Diagnosed Cases of Dyslipidemia in Greece (2019–2032)

Figure 20: Gender-specific Diagnosed Cases of Dyslipidemia in Greece (2019–2032)

Figure 21: Prevalence of Genetic Dyslipidemia by Types in Greece (2019–2032)

Figure 22: Lipid-specific Diagnosed Cases in Greece (2019–2032)

Figure 23: Prevalent Cases of Dyslipidemia in Turkey (2019–2032)

Figure 24: Diagnosed Cases of Dyslipidemia in Turkey (2019–2032)

Figure 25: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey (2019–2032)

Figure 26: Prevalence of Genetic Dyslipidemia by Types in Turkey (2019–2032)

Figure 27: Lipid-specific Diagnosed Cases in Turkey (2019–2032)

Figure 28: Prevalent Cases of Dyslipidemia in Poland (2019–2032)

Figure 29: Diagnosed Cases of Dyslipidemia in Poland (2019–2032)

Figure 30: Gender-specific Diagnosed Cases of Dyslipidemia in Poland (2019–2032)

Figure 31: Prevalence of Genetic Dyslipidemia by Types in Poland (2019–2032)

Figure 32: Lipid-specific Diagnosed Cases in Poland (2019–2032)

Figure 33: Prevalent Cases of Dyslipidemia in the Netherlands (2019–2032)

Figure 34: Diagnosed Cases of Dyslipidemia in the Netherlands (2019–2032)

Figure 35: Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands (2019–2032)

Figure 36: Prevalence of Genetic Dyslipidemia by Types in the Netherlands (2019–2032)

Figure 37: Lipid-specific Diagnosed Cases in the Netherlands (2019–2032)

Figure 38: Prevalent Cases of Dyslipidemia in Belgium (2019–2032)

Figure 39: Diagnosed Cases of Dyslipidemia in Belgium (2019–2032)

Figure 40: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium (2019–2032)

Figure 41: Prevalence of Genetic Dyslipidemia by Types in Belgium (2019–2032)

Figure 42: Lipid-specific Diagnosed Cases in Belgium (2019–2032)

Figure 43: Cases of Dyslipidemia in Austria (2019–2032)

Figure 44: Diagnosed Cases of Dyslipidemia in Austria (2019–2032)

Figure 45: Gender-specific Diagnosed Cases of Dyslipidemia in Austria (2019–2032)

Figure 46: Prevalence of Genetic Dyslipidemia by Types in Austria (2019–2032)

Figure 47: Lipid-specific Diagnosed Cases in Austria (2019–2032)

Forward to Friend

Need A Quote